Abstract
EKR Therapeutics business deal was announced on the 10th of March 2008. The business deal comprised investment from various investors, new as well as existing ones, which accounted for $50 million. EKR Therapeutics Inc was the company where all the investments were made.
Investors in the EKR Therapeutics business deal:
The following investors made their contribution towards the business deal.
- ESP Equity Partners
- MPM Capital
- Quaker BioVentures
- LLR Partners
- New Spring Capital
Among the list of above investors in the EKR Therapeutics business deal, LLR Partners along with MPM Capital were the new investors, the rest being pre existing investors of the company (EKR Therapeutics Inc).
The company- EKR Therapeutics Inc:
It is a private company, which specializes in pharmaceuticals. EKR Therapeutics Inc was established in the year 2005. The company is engaged in commercializing, acquiring and developing proprietary products, which help in pain management, cardiovascular conditions and medications for oncology support. EKR Therapeutics Inc has served unmet requirements in the field of medicine. It aims to excel in acute care medications. It also extends quality service to the patients and conducts medical education projects from time to time. Owing to its optimum standards, the company has won the confidence of so many investors for financing different projects worked out by it.
Utilization of the capital raised from the EKR Therapeutics business deal:
From the money raised, a part of it would be used for pursuing the acquisition of candidates for magnifying its "acute care products" portfolio. By acquiring Cardene franchise in early 2008, the company's portfolio was magnified. The company also intends to carry out further acquisitions. Alternatively, it also plans to work upon its product portfolio.